

A Recessive Genetic Model and Runs of Homozygosity in Major Depressive Disorder

Robert A. Power,^{1*} Matthew C. Keller,^{2,3} Stephan Ripke,^{4,5} Abdel Abdellaoui,⁶ Naomi R. Wray,⁷ Patrick F. Sullivan,^{8,9,10,11} MDD PGC Working Group, and Gerome Breen^{1,12,13}

¹MRC Social Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, United Kingdom

²Department of Psychology and Neuroscience, University of Colorado at Boulder, Boulder, Colorado

³Institute for Behavioral Genetics, University of Colorado at Boulder, Boulder, Colorado

⁴Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts

⁵Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts

⁶Department of Biological Psychology, VU University Amsterdam, Amsterdam, The Netherlands

⁷The University of Queensland, Queensland Brain Institute, Brisbane, Australia

⁸Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

⁹Department of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

¹⁰Department of Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

¹¹Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

¹²NIHR Biomedical Research Centre for Mental Health, South London and Maudsley NHS Foundation Trust, London, United Kingdom

¹³Institute of Psychiatry, King's College London, London, United Kingdom

Manuscript Received: 22 July 2013; Manuscript Accepted: 22 November 2013

The authors declare no conflicts of interest.

Grant sponsor: NIMH; Grant numbers: MH085520, MH080403, MH072802; Grant sponsor: German Federal Ministry of Education and Research; Grant number: 01GS08144 01GS08147; Grant sponsor: NIMH R01; Grant numbers: MH061686, MH059542, MH075131, MH059552, MH059541, MH060912; Grant sponsor: Broad Institute Center; Grant number: U54 RR020278; Grant sponsor: National Alliance for Research on Schizophrenia and Depression; Grant sponsor: BMBF Program Molecular Diagnostics: Validation of Biomarkers for Diagnosis and Outcome in Major Depression; Grant number: 01ES0811; Grant sponsor: Bavarian Ministry of Commerce, and the Federal Ministry of Education and Research (BMBF) in the framework of the National Genome Research Network; Grant numbers: FKZ 01GS0481, 01GS08145; Grant sponsor: The Netherlands Study of Depression and Anxiety (NESDA) and the Netherlands Twin Register (NTR); Grant sponsor: The Netherlands Organization for Scientific Research; Grant numbers: 904-61-090, 985-10-002, 904-61-193, 480-04-004, 400-05-717, 912-100-20, 916-76-125; Grant sponsor: Spinozapremie; Grant number: 56-464-14192; Grant sponsor: Geestkracht program; Grant number: 10-000-1002; Grant sponsor: The Center for Medical Systems Biology (NWO Genomics), Biobanking and Biomolecular Resources Research Infrastructure, VU University's Institutes for Health and Care Research and Neuroscience Campus Amsterdam, BIC/BioAssist/RK; Grant number: 2008.024; Grant sponsor: The European Science Foundation; Grant number: EU/QLRT-2001-01254; Grant sponsor: The European Community's Seventh Framework Program; Grant number: FP7/2007-2013; Grant sponsor: ENGAGE; Grant number: HEALTH-F4-2007-201413; Grant sponsor: The European Science Council; Grant number: ERC 230374; Grant sponsor: Genetic Association Information Network (GAIN) of the Foundation for

the US National Institutes of Health (partial support); Grant sponsor: GAIN and the NIMH; Grant number: MH081802; Grant sponsor: Australian National Health and Medical Research Council; Grant numbers: 241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496675, 496739, 552485, 552498, 613602, 613608, 613674, 619667; Grant sponsor: The Australian Research Council; Grant numbers: FT0991360, FT0991022; Grant sponsor: The FP-5 GenomEUtwin Project; Grant number: QL2-CT- 2002-01254; Grant sponsor: The US National Institutes of Health; Grant numbers: AA07535, AA10248, AA13320, AA13321, AA13326, AA14041, MH66206, DA12854, DA019951; Grant sponsor: The Center for Inherited Disease Research (Baltimore, MD, USA); Grant sponsor: UK Medical Research Council and GlaxoSmithKline; Grant number: G0701420; Grant sponsor: The National Institute for Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health at the South London; Grant sponsor: Maudsley NHS Foundation Trust; Grant sponsor: The Institute of Psychiatry, King's College London; Grant sponsor: The UK Medical Research Council; Grant number: G0000647; Grant sponsor: European Commission Framework; Grant number: LSHB-CT-2003-503428; Grant sponsor: National Institute of Mental Health; Grant number: N01MH90003.

*Correspondence to:

Robert A. Power, MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London SE5 8AF, United Kingdom.

E-mail: robert.r.power@kcl.ac.uk

Article first published online in Wiley Online Library (wileyonlinelibrary.com): 30 January 2014

DOI 10.1002/ajmg.b.32217

Genome-wide association studies (GWASs) of major depressive disorder (MDD) have yet to identify variants that surpass the threshold for genome-wide significance. A recent study reported that runs of homozygosity (ROH) are associated with schizophrenia, reflecting a novel genetic risk factor resulting from increased parental relatedness and recessive genetic effects. Here, we explore the possibility of such a recessive model in MDD. In a sample of 9,238 cases and 9,521 controls reported in a recent mega-analysis of 9 GWAS we perform an analysis of ROH and common variants under a recessive model. Since evidence for association with ROH could reflect a recessive mode of action at loci, we also conducted a genome-wide association analyses under a recessive model. The genome-wide association analysis using a recessive model found no significant associations. Our analysis of ROH suggested that there was significant heterogeneity of effect across studies in effect ($P=0.001$), and it was associated with genotyping platform and country of origin. The results of the ROH analysis show that differences across studies can lead to conflicting systematic genome-wide differences between cases and controls that are unaccounted for by traditional covariates. They highlight the sensitivity of the ROH method to spurious associations, and the need to carefully control for potential confounds in such analyses. We found no strong evidence for a recessive model underlying MDD.

© 2014 Wiley Periodicals, Inc.

Key words: runs of homozygosity; recessive risk model; major depression; inbreeding

INTRODUCTION

Major depressive disorder (MDD) is one of the leading burdens of disease in the world, with a lifetime prevalence of $\sim 15\%$ [Kessler et al., 2003; Hasin et al., 2005]. It has been found to be moderately heritable, from 31% to 42% [Sullivan et al., 2000], though with greater heritability in severe, recurrent forms of the disorder [McGuffin et al., 1996; Levinson, 2006]. A recent mega-analysis of nine genome-wide association studies found no significant associations with individual genetic variants (Psychiatric Genomics Consortium MDD Working Group, 2012), compared to ~ 5 genome-wide significant associations in similar sized studies of other psychiatric disorders [Ripke et al., 2011; Sklar et al., 2011]. These association studies are conducted under an additive model, while the true effects of some risk variants may be recessive, for which individuals with two copies of an allele are at greater risk than would be predicted from twice a single allele's effect. In a fully recessive model only those with two copies of the risk allele are at risk, though there is also the possibility of partial recessive effects. As selection acts to remove deleterious alleles with respect to overall fitness from the population, genetic risk variants that are recessive can escape selection longer. Inbreeding within families (e.g. consanguineous marriages) often exposes such recessive alleles due to an increased likelihood of alleles at each locus being identical by descent. Until recently studies of inbreeding were focused on families or communities in which inbreeding is expressed relative to the founder generation, which is assumed to be unrelated and where inbreeding information was determined from self-reports or

How to Cite this Article:

Power RA, Keller MC, Ripke S, Abdellaoui A, Wray NR, Sullivan PF, Breen G. 2014. A recessive genetic model and runs of homozygosity in major depressive disorder. *Am J Med Genet Part B* 165B:157–166.

knowledge of pedigrees (pedigree inbreeding). For example, Rudan et al. [2003] found a higher incidence of six complex genetic diseases/disorders including MDD among Croatian villages with higher levels of pedigree inbreeding [Rudan et al., 2003]. By using genome-wide genotype data it is also possible to estimate an individual's inbreeding from more distant common ancestors to provide evidence for whether a recessive genetic model is more appropriate for a disorder.

One method to analyse the effect of inbreeding from genome-wide genotype data is to identify segments of continuous homozygous SNPs, reflecting blocks of the genome that are identical by descent from a common ancestor. Runs of homozygosity (ROH) capture inbreeding effects that are due to common or rare causal variants better than a simple measure of excess number of homozygous SNPs across the genome, which tends to only capture the recessive effects of common variants [Keller et al., 2011]. An association between percentage of genome covered by ROH (F_{ROH}) and schizophrenia has been reported [Keller et al., 2012]. Due to the possibility of genetic overlap between MDD and schizophrenia [Schulze et al., 2012; Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013], a similar association between F_{ROH} and MDD might be expected. However, MDD has a lower heritability ($h^2 \sim 0.37$, Sullivan et al., 2000) than schizophrenia ($h^2 \sim 0.81$, Sullivan et al., 2003), which should attenuate genetic relationships. Moreover, some authors have suggested that MDD may not be under negative selection and the casual genetic variants may be beneficial in some circumstances [Nesse, 1999; Watson and Andrews, 2002; Belsky and Pluess, 2009; Power et al., 2013]. Here we look at the association between MDD and SNPs in 9,238 cases and 9,521 controls across nine studies (Table 1) [Psychiatric Genomics Consortium MDD Working Group, 2012] under a recessive genetic model. We also use genome-wide estimates of inbreeding to look for a consistent difference between cases and controls across nine studies of MDD, in order to support a recessive model of the disorder.

MATERIAL AND METHODS

Sample

In this report, we analyzed individual data from the nine discovery samples [Ising et al., 2009; Sullivan et al., 2009; Lewis et al., 2010; Muglia et al., 2010; Rietschel et al., 2010; Shi et al., 2011; Shyn et al., 2011; Wray et al., 2012] of the PGC-MDD that together comprise 9,238 cases and 9,521 controls. Full sample details are given in the supplementary materials of the original analysis (Psychiatric Genomics Consortium MDD Working Group, 2012), and are outlined in Table 1. All subjects were of European

TABLE 1. Summary Statistics of Each of the Nine Studies and Results of Homozygosity Analysis

Study	N		Platform	Recurrence (%)	Ascertainment	Country	Number of SNPs ^a	Mean F _{ROH} (%) ^b	SD of Mean F _{ROH} (%) ^b	Traditional F estimate (%) ^c	Mean size of ROH (kb)	SD for Mean size of kb	Ref
	cases	controls											
RADIANT UK	1,625	1,588	Illumina 610k	97.1	Clinical	UK	263,728	0.10	0.41	0.1	3,294	1,373	Lewis et al. [2010]
MDD2000 QIMR-610k	433	751	Illumina 610k	57.6	Population	Australia	275,259	0.09	0.19	-0.01	3,376	1,049	Wray et al. [2012]
MDD2000 QIMR-317k	1,017	960	Illumina 317k ^d	51.4	Population	Australia	210,075	0.09	0.24	0.06	3,330	937	Wray et al. [2012]
Radiant + Bonn/Mannheim	935	1,290	Illumina 610k	74.2	Clinical	Germany	260,561	0.10	0.30	0.06	3,580	1,565	Rietschel et al. [2010]
GAIN	1,694	1,767	Perlegen 600k	50.7	Clinical/population	The Netherlands	199,749	0.12	0.36	0.15	3,780	1,840	Sullivan et al. [2009]
GenRED	1,030	1,253	Affymetrix 6.0	100	Volunteers	USA	253,826	0.08	0.18	0.09	3,238	763	Shi et al. [2011]
GSK	887	864	Illumina 550k	100	Clinical	Germany	281,029	0.16	0.67	0.14	3,732	1,711	Muglia et al. [2010]
MPIP	376	537	Illumina 317k	36.7	Clinical	Germany	215,393	0.11	0.30	0.04	3,533	1,424	Ising et al. [2009]
STAR*D	1,241	511	Affymetrix 5.0	74.3	Clinical	USA	155,428	0.10	0.40	0.17	3,362	783	Shyn et al. [2011]

^aGenotyping was on either Illumina 317k or Illumina 370k SNPs, but only SNPs from Illumina 317k were used for imputation.

^bAfter QC and pruning on linkage disequilibrium.

^cF_{ROH} is the percentage of the genome covered by runs of homozygosity.

^dThis measure of F reflects an individual's observed number of homozygous loci compared to that expected under Hardy-Weinberg equilibrium.

ancestry (as determined from genome-wide genotypes). Cases were required to have diagnoses of DSM-IV lifetime MDD established using structured diagnostic instruments from direct interviews by trained interviewers (two studies required recurrent MDD and one recurrent, early-onset MDD) or clinician-administered DSM-IV checklists. Studies ascertained cases mostly from clinical sources, and controls were largely randomly selected from the population and screened for lifetime history of MDD.

Method of ROH Calling and Analysis

Genotyping was described in the supplementary materials in the original analysis (Psychiatric Genomics Consortium MDD Working Group, 2012). All samples were genotyped with single nucleotide polymorphism (SNP) arrays of greater than 200 K genome-wide SNPs, with analysis restricted to polymorphic SNP probes. In the original analysis, imputation to the CEU HapMap3 reference sample [Altshuler et al., 2010], 1,235,109 autosomal SNPs, was performed using Beagle 3.0.4 [Browning and Browning, 2009]. In order to perform an association analysis under a recessive model or call runs of homozygosity (ROH), imputed SNP dosage data was converted to discrete genotype calls, keeping those SNPs with a probability of at least 0.95. The use of imputed SNPs helped to increase similarity of genomic coverage across studies. SNPs with a missingness of >2% or minor allele frequency (MAF) <5% were removed, as were then individuals with missingness over 2%. Prior to analysis SNPs were pruned for LD within PLINK, removing any SNPs with an R² 0.90 with any other SNP in a 50 SNP window. The use of imputed data in ROH has previously been shown to give similar results to those restricting to only genotyped SNPs [Keller et al., 2012]. The calling of ROH and percentage of genome covered by ROH per individual (F_{ROH}) were derived within PLINK [Purcell et al., 2007] following the same method found to optimally detect effects of autozygosity, as described in Howrigan et al. [2011]. In particular, we used a series of sliding windows across the genome to call ROH within each individual separately. The size of the windows was set to 65 consecutive SNPs, so any single SNP would be found in 65 different windows. If at least four (>5%) of these windows contained entirely homozygous SNPs, then the SNP in question could be included within a ROH. Within windows, one missing SNP was allowed. To avoid false positives, only ROH with a minimum of 65 consecutive SNPs covering 2.3 Mb were used when calculating F_{ROH}. In addition, the required minimum density in a ROH was set at 200 kb per SNP and the maximum gap between two consecutive homozygous SNPs was set at 500 kb. The estimate of the total genome captured was 2.77 × 10⁹ bp. The analysis was performed by study, using F_{ROH} as a predictor of case-control status in a logistic regression. Percentage of SNPs missing, a SNP-by-SNP measure of homozygosity determined by PLINK's—het command, and the first five ancestry-informative principal components were used as covariates. The SNP-by-SNP measure of homozygosity was included to correct for differences in genomic-homozygosity levels unrelated to inbreeding, such as DNA quality or population ancestry. A mixed model was also examined combining all samples, using study as a random effect. This analysis was performed in STATA [StataCorp., 2011].

Genome-Wide Recessive Model

The genome-wide recessive model analysis used the autosomal dosage data converted to genotype calls as described above in the analysis of ROH. Analyses was performed in PLINK [Purcell et al., 2007], using the `--recessive` command. The first five ancestry-informative principal components were included as covariates. Analysis was restricted to autosomes. Each study was analysed separately and then a meta-analysis was performed for each SNP across studies (using fixed effect P -value in PLINK). As the risk allele is set as the minor allele by default, and this may differ by study for alleles at frequencies near 0.5, we used the minor allele in the analysis of imputed data from the whole sample as a reference. A P -value $< 5 \times 10^{-8}$ was considered as genome-wide significant. For this significance cut-off, we had 90% power to detect a relative risk of 1.47 for the rare recessive genotype for SNPs with a MAF from 0.3 to 0.5. However, power decreased rapidly for those alleles with lower MAF, with 90% power to detect those with a relative risk of 1.81 and MAF of 0.2, or with a relative risk of 2.21 and MAF of 0.15. For those SNPs with lower MAF, power reduced rapidly for a recessive model. Calculations were performed using CaTS Power Calculator [Skol et al., 2006].

RESULTS

Across all samples the average percentage of the genome covered by ROH (F_{ROH}) was 0.11% (95% CI 0.102–0.112; Table 1), similar albeit slightly lower than average F_{ROH} (0.15%) reported in an earlier report using the same parameters [Keller et al., 2012]. In our mixed model analysis across all samples with study as a random effect, we found no significant effect of F_{ROH} on MDD status. However, there was substantial heterogeneity in direction of effect across studies ($P=0.001$, Fig. 1). Overall, four studies showed increased F_{ROH} in cases (one significantly, $P=0.007$), while five studies showed increased F_{ROH} in controls (one where $P=0.005$). Including further principal components (up to 20) and increasing ROH size (up to 170 SNPs) made no difference to the heterogeneity of the results.

To explore this apparent heterogeneity we examined two features of the included studies that might provide insight into the results. The first issue was potential poor matching of cases and controls, which we tested within the combined RADIANT German and Bonn-Mannheim sample. Here cases were recruited from both of these two studies, whereas the controls were collected and genotyped only as part of the Bonn-Mannheim study. However, excluding the RADIANT cases and restricting to only the matched Bonn-Mannheim study's cases and controls still resulted in a significant association with ROH ($P=0.03$), as both sets of cases were found to have similar mean F_{ROH} . This tentatively suggested that the heterogeneity apparent across studies was not replicated within studies recruited from the same geographic region. Secondly, we were interested in the effects of genomic coverage on ROH. Cases and controls from the Queensland Institute of Medical Research (QIMR) were recruited as one sample but included as two independent cohorts, based on their genotyping platform (Illumina 317k and 610k chips). When we restricted the analysis to only those SNPs directly genotyped on both platforms




FIG. 1. Beta coefficient from logistic regression of F_{ROH} predicting MDD per study (with 95% CI, accounting for covariates). Positive effects suggest that ROHs are a risk factor for MDD. Note that though no combined effect in the mixed model of the full sample, in Illumina studies increased F_{ROH} was a risk factor ($P=0.02$) and in non-Illumina studies it was protective ($P=0.007$). Note also the consistency in studies from the same country: *Australian studies; ~American studies; #German studies.

(202,062 SNPs), we found that the mean F_{ROH} for the QIMR-610k sample reduced from 0.086% to 0.077%, compared to 0.078% for the QIMR-317k sample. This implies, as expected, that genotyping platform and genome coverage were influencing estimates of mean F_{ROH} .

To better understand potential sources of heterogeneity in our findings, we used a linear meta-regression with a study's effect size as the outcome and features of the studies individually analysed as predictors. We tested percentage of cases with recurrent MDD, mean F_{ROH} and genome-wide homozygosity, country of recruitment, presence of copy number variant probes on the platform, and genotyping platform as potential predictors of direction of effect (see Supplementary Table 1). Genotyping platform was nominally associated with effect size ($P=0.05$), and the direction of effect of F_{ROH} differed when studies on non-Illumina platforms were analysed separately. Within the three non-Illumina genotyped studies, increased inbreeding was protective against MDD ($P=0.007$) while within the six Illumina genotyped studies inbreeding was a significant risk factor for MDD ($P=0.02$). We noted that when more than one study was recruited from a country, the direction of effect for ROH was consistent across all studies recruited from the same country (see Fig. 1). However, this was only a significant predictor in the meta-regression when distinguishing between German and non-German studies ($P=0.02$). This level of confounding from genotyping and country likely reduced our power to detect a true effect of ROH and MDD.

In the meta-analysis of a recessive model of association, 929, 138 SNPs were analysed, though not all appeared in all nine studies due to differences in genotyping coverage. The most significant recessive association was for rs13261582 on chromosome 8 in an intergenic region between *SNTB1* and *HAS2* (odds ratio of 2.0 for the minor A allele, MAF 0.22, $P = 2.58 \times 10^{-6}$). However this SNP was only present in two studies (GenRED and STAR*D), and so is only supported by a subset of the sample. It did not appear among the reported top SNPs from the primary analysis of this dataset under an additive genetic model in the full sample ($P = 0.12$). The results of the meta-analysis also showed a lower median P -value than expected by chance (λ_{GC} 0.97, see Supplementary Figs. 1 and 2 for Manhattan and QQ plots). The λ_{GC} was 1.03 for SNPs with MAF > 0.2 and 0.90 for SNPs with MAF < 0.2 , implying smaller differences of genotype frequencies between cases and controls than expected by chance for SNPs with low MAF. This is possibly the result of the less accurate imputation of rare alleles, or a lack of power.

DISCUSSION

Our analyses show systematic differences in F_{ROH} between cases and controls that differ in direction across studies. There are several explanations for these results, mostly highlighting limitations of this analysis. Firstly, we found systematic differences in mean F_{ROH} between studies. This is not unexpected and likely reflects the density of the genomic coverage and the accuracy of imputation, since SNPs were restricted to those with high quality imputation. A similar level of variation in F_{ROH} was observed in the Psychiatric GWAS Consortium's analysis of F_{ROH} across 17 studies of schizophrenia [Keller et al., 2012], though they did not report any heterogeneity of effect as a function of genotyping platform or country of recruitment. It seems unlikely that the heterogeneity of effect in the present study could be the result of differing SNP inclusion on the platforms, because such an explanation would imply systematic differences between cases and controls in the probability of homozygosity across SNPs as a function of platform. More likely in our opinion is the possibility that factors related to ascertainment of cases and controls differed across studies and influenced overall homozygosity. Such factors could include changes in homozygosity levels due to length and quality of DNA storage, or differences in ascertainment of cases and controls across populations. It is noteworthy that the two out of nine studies that genotyped controls independently of cases (GenRED and STAR*D) both showed higher F_{ROH} in controls than cases. Further, studies appear to cluster by country of origin and direction of the effect of F_{ROH} . All three German studies had increased F_{ROH} in cases for example, while the two Australian and two US studies all showed increased F_{ROH} in controls. This may reflect confounding demographic factors specific to each country. These unknown confounders, such as urban/rural status or religion, that influence both distant inbreeding (F_{ROH}) and MDD could explain the differences in effects between studies. A recent analysis of ROH and MDD in a partially overlapping sample of the GAIN study analysed here found exactly that. Religion confounded of the association due to reduced levels of depression but increased inbreeding in within the religious population of the Netherlands

[Abdellaoui et al., 2013]. Certainly the initial hypothesis of this study, that an association with inbreeding would reflect negative selection on MDD and an excess of recessive causal mutations, seems an implausible explanation for the observed heterogeneity as the evolutionary cost of MDD status seems unlikely to have differed greatly among the ancestors of those included in the present study. Any of these explanations for the results of the F_{ROH} analysis may give some insight into why the original mega-analysis of these nine studies did not lead to any replicable genome-wide significant findings.

Our results from the genome-wide association analysis of MDD also produced no evidence for a recessive model, failing to produce any genome-wide significant associations. It is possible that our underlying model of recessive effect is unsuitable for an outbred population. Here we looked at a recessive effect for the minor allele, but two alternate models may also have been viable: compound heterozygosity and overdominance. Compound heterozygosity is an additional risk in individuals carrying two recessive but non-identical alleles within a genetic locus, while overdominance is the increased risk of homozygosity of any allele compared to being heterozygous. However, our analysis of both would have been restricted by low power and the use of biallelic markers, and were, therefore, not performed. Both the GWAS and ROH analyses suggest though that there is no underlying recessive model of MDD, at least not of large effect. Such an association was previously reported for schizophrenia in a similarly sized sample [Keller et al., 2012], showing an increase of risk for schizophrenia by 17% for every additional percentage of the genome covered by ROH and was taken as evidence for historical selection against schizophrenia risk variants. The lack of a similar association here adds molecular evidence to that from epidemiological studies suggesting MDD has little impact on reproductive fitness compared to other psychiatric disorders, and so is under substantially less negative selection [e.g., Power et al., 2013].

These results highlight that the analysis of F_{ROH} appears to be sensitive to systematic differences between studies that are ostensibly unrelated to MDD status, potentially give rise to either false positive or false negative results. This suggests there are genome-wide differences in homozygosity and/or inbreeding between populations that are not corrected for by methods such as ancestry-informative principal components. We recommend the use of large combined samples in the analysis of F_{ROH} as a predictor of traits and disorders, due to the high risk of spurious associations within one study. Preferably such analyses should be done with access to data on potential social and demographic confounders. One possible further improvement might be the development of novel methods for analysing ROH, particularly in imputed genotype data where probability for homozygosity across a region is available. As similar heterogeneity across studies was not seen in other analyses of ROH within consortia [Keller et al., 2012; McQuillan et al., 2012], the significant heterogeneity in our results suggest that MDD is particularly sensitive to differing demographics in the ascertainment of cases and controls and this may present a problem to genome-wide polygenic approaches such as ROH. Certainly no strong evidence for a recessive model was apparent, supporting the view of MDD being under weaker negative selection than other psychiatric disorders.

ACKNOWLEDGMENTS

Collaborators:

Michael R	Barnes	GlaxoSmithKline	UK
Thomas	Bettecken	Max Planck Institute of Psychiatry	Germany
Elisabeth B	Binder	Max Planck Institute of Psychiatry	Germany
Douglas HR	Blackwood	University of Edinburgh	UK
Dorret I	Boomsma	VU University, Amsterdam	The Netherlands
Gerome	Breen	Institute of Psychiatry, King's College London	UK
René	Breuer	Central Inst Mental Health, University of Heidelberg	Germany
Enda M	Byrne	Queensland Institute of Medical Research	Australia
Sven	Cichon	University of Bonn	Germany
William H	Coryell	University of Iowa	USA
Nick	Craddock	Cardiff University	UK
Ian W	Craig	Institute of Psychiatry, King's College London	UK
Darina	Czamara	Max Planck Institute of Psychiatry	Germany
Eco J	De Geus	VU University, Amsterdam	The Netherlands
Franziska	Degenhardt	University of Bonn	Germany
Anne E	Farmer	Institute of Psychiatry, King's College London	UK
Josef	Frank	Central Inst Mental Health, University of Heidelberg	Germany
Scott D	Gordon	Queensland Institute of Medical Research	Australia
Magdalena	Gross	University of Bonn	Germany
Steven P	Hamilton	University of California, San Francisco	USA
Andrew C	Heath	Washington University, St Louis	USA
Anjali K	Henders	Queensland Institute of Medical Research	Australia
Stefan	Hermes	University of Bonn	Germany
Ian B	Hickie	University of Sydney, Sydney	Australia
Susanne	Hoefels	University of Bonn	Germany
Florian	Holsboer	Max Planck Institute of Psychiatry	Germany
Witte J	Hoogendijk	Erasmus Medical Center	The Netherlands
Jouke Jan	Hottenga	VU University, Amsterdam	The Netherlands
Marcus	Ising	Max Planck Institute of Psychiatry	Germany
Ian	Jones	Cardiff University	UK
Lisa	Jones	University of Birmingham	UK
Tzeng	Jung-Ying	North Carolina State University	USA
James A	Knowles	University of Southern California	USA
Martin A	Kohli	Max Planck Institute of Psychiatry	Germany
Ania	Korszun	Queen Mary University of London	UK
William B	Lawson	Howard University	USA
Douglas F	Levinson	Stanford University	USA
Cathryn M	Lewis	Institute of Psychiatry, King's College London	UK
Danyu	Lin	University of North Carolina	USA
Susanne	Lucae	Max Planck Institute of Psychiatry	Germany
Donald	MacIntyre	University of Edinburgh	UK
Pamela AF	Madden	Washington University, St Louis	USA
Wolfgang	Maier	University of Bonn	Germany
Nicholas G	Martin	Queensland Institute of Medical Research	Australia
Manuel	Mattheisen	University of Bonn	Germany
Patrick J	McGrath	Columbia University	USA
Peter	McGuffin	Institute of Psychiatry, King's College London	UK
Andrew	McIntosh	University of Edinburgh	UK
Alan	McLean	University of Edinburgh	UK
Christel M	Middeldorp	VU University, Amsterdam	The Netherlands
Lefkos	Middleton	Imperial College	UK
Grant M	Montgomery	Queensland Institute of Medical Research	Australia
Pierandrea	Muglia	GlaxoSmithKline	Italy
Bertram	Müller-Myhok	Max Planck Institute of Psychiatry	Germany
Benjamin	Neale	Harvard University/Broad Institute	USA
Markus M	Noethen	University of Bonn	Germany
Willem A	Nolen	Groningen University Medical Center	The Netherlands
Dale R	Nyholt	Queensland Institute of Medical Research	Australia

Brenda P	Penninx	VU University Medical Center, Amsterdam	The Netherlands
Michele L	Pergadia	Washington University, St Louis	USA
James B	Potash	University of Iowa	USA
Marcella	Rietschel	Central Inst Mental Health, University of Heidelberg	Germany
Stephan	Ripke	Harvard University/Broad Institute	USA
William A	Scheftner	Rush University Medical Center	USA
Thomas G	Schulze	University of Goettingen	USA
Jianxin	Shi	National Cancer Institute	USA
Stanley I	Shyn	University of Washington	USA
Susan L	Slager	Mayo Clinic	USA
Johannes H	Smit	VU University Medical Center, Amsterdam	The Netherlands
Michael	Steffens	University of Bonn	Germany
Patrick F	Sullivan	University of North Carolina	USA
Federica	Tozzi	GlaxoSmithKline	Italy
Jens	Treutlein	Central Inst Mental Health, University of Heidelberg	Germany
Manfred	Uhr	Max Planck Institute of Psychiatry	Germany
Edwin JCG	van den Oord	Virginia Commonwealth University	USA
Gerard	VU University Medical Center, Amsterdam	The Netherlands	
Myrna M	Weissman	Columbia University	USA
Gonneke	Willemsen	VU University, Amsterdam	The Netherlands
Naomi R	Wray	The University of Queensland	Australia
Frans G	Zitman	Leiden University Medical Center, Leiden	The Netherlands

The PGC was funded by NIMH Grants MH085520 (lead PI PFS) and MH080403. The Bonn/Mannheim (BoMa) GWAS was supported by the German Federal Ministry of Education and Research, within the context of the National Genome Research Network 2 (NGFN-2), the National Genome Research Network plus (NGFNplus) and the Integrated Genome Research Network (IG) MooDS (Grant 01GS08144 to S. Cichon and M.M. Nothen, and Grant 01GS08147 to M. Rietschel). The GenRED GWAS project was supported by NIMH R01 Grants MH061686 (D.F. Levinson), MH059542 (W.H. Coryell), MH075131 (W.B. Lawson), MH059552 (J.B. Potash), MH059541 (W.A. Scheftner) and MH060912 (M.M. Weissman). We acknowledge the contributions of Dr. George S. Zubenko and Dr. Wendy N. Zubenko, Department of Psychiatry, University of Pittsburgh School of Medicine, to the GenRED I project. The NIMH Cell Repository at Rutgers University and the NIMH Center for Collaborative Genetic Studies on Mental Disorders made essential contributions to this project. Genotyping was carried out by the Broad Institute Center for Genotyping and Analysis with support from Grant U54 RR020278 (which partially subsidized the genotyping of the GenRED cases). Collection and quality control analyses of the control data set were supported by grants from NIMH and the National Alliance for Research on Schizophrenia and Depression. We are grateful to Knowledge Networks (Menlo Park, CA, USA) for assistance in collecting the control data set. We express our profound appreciation to the families who participated in this project, and to the many clinicians who facilitated the referral of participants to the study. Max Planck Institute of Psychiatry MARS study was supported by the BMBF Program Molecular Diagnostics: Validation of Biomarkers for Diagnosis and Outcome in Major Depression (01ES0811). Genotyping was supported by the Bavarian Ministry of Commerce, and the Federal Ministry of Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN2

and NGFN-Plus, FKZ 01GS0481 and 01GS08145). The Netherlands Study of Depression and Anxiety (NESDA) and the Netherlands Twin Register (NTR) contributed to GAIN-MDD and to MDD2000. Funding was from: the Netherlands Organization for Scientific Research (Mag W./Zon M.W. Grants 904-61-090, 985-10-002, 904-61-193, 480-04-004, 400-05-717, 912-100-20; Spinozapremie 56-464-14192; Geestkracht program Grant 10-000-1002); the Center for Medical Systems Biology (NWO Genomics), Biobanking and Biomolecular Resources Research Infrastructure, VU University's Institutes for Health and Care Research and Neuroscience Campus Amsterdam, BIC/BioAssist/RK (2008.024); the European Science Foundation (EU/QLRT-2001-01254); the European Community's Seventh Framework Program (FP7/2007-2013); ENGAGE (HEALTH-F4-2007-201413); and the European Science Council (ERC, 230374). Genotyping was funded in part by the Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health, and analysis was supported by grants from GAIN and the NIMH (MH081802). CM Middelorp was supported by the Netherlands Organization for Scientific Research (NOW-VENI grant 916-76-125). Funding for the QIMR samples was provided by the Australian National Health and Medical Research Council (241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496675, 496739, 552485, 552498, 613602, 613608, 613674, 619667), the Australian Research Council (FT0991360, FT0991022), the FP-5 GenomeUtwinn Project (QLG2-CT-2002-01254) and the US National Institutes of Health (AA07535, AA10248, AA13320, AA13321, AA13326, AA14041, MH66206, DA12854, DA019951), and the Center for Inherited Disease Research (Baltimore, MD, USA). We thank the twins and their families registered at the Australian Twin Registry for their participation in the many studies that have contributed to this research. RADIANT was funded by: a joint grant from the UK Medical

Research Council and GlaxoSmithKline (G0701420); the National Institute for Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King's College London; and the UK Medical Research Council (G0000647). This work was funded in part by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and [Institute of Psychiatry] King's College London. This article/paper/report presents independent research in part funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The GENDEP study was funded by a European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-2003-503428. Genotyping of STAR*D was supported by an NIMH Grant to S.P. Hamilton (MH072802). STAR*D was funded by the National Institute of Mental Health (contract N01MH90003) to the University of Texas Southwestern Medical Center at Dallas (A.J. Rush, principal investigator). We would like to thank the numerous researchers within the Psychiatric GWAS Consortium for their contributions. We also thank the thousands of people with MDD who donated time and effort to make this research possible.

REFERENCES

- Abdellaoui A, Hottenga JJ, Xiao X, Scheet P, Ehli EA, Davies GE, Hudziak JJ, Smit DJ, Bartels M, Willemsen G, Brooks A, Sullivan PF, Smit JH, de Geus EJ, Penninx BW, Boomsma DI. 2013. Association between autozygosity and major depression: Stratification due to religious assortment. *Behav Genet* 43(6):455–467.
- Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, Yu F, Bonnen PE, de Bakker PI, Deloukas P, Gabriel SB, Gwilliam R, Hunt S, Inouye M, Jia X, Palotie A, Parkin M, Whittaker P, Chang K, Hawes A, Lewis LR, Ren Y, Wheeler D, Muzny DM, Barnes C, Darvishi K, Hurler M, Korn JM, Kristiansson K, Lee C, McCarroll SA, Nemesh J, Keinan A, Montgomery SB, Pollack S, Price AL, Soranzo N, Gonzaga-Jauregui C, Anttila V, Brodeur W, Daly MJ, Leslie S, McVean G, Moutsianas L, Nguyen H, Zhang Q, Ghorji MJ, McGinnis R, McLaren W, Takeuchi F, Grossman SR, Shlyakhter I, Hostetter EB, Sabeti PC, Adebamowo CA, Foster MW, Gordon DR, Licinio J, Manca MC, Marshall PA, Matsuda I, Ngare D, Wang VO, Reddy D, Rotimi CN, Royal CD, Sharp RR, Zeng C, Brooks LD, McEwen JE. 2010. Integrating common and rare genetic variation in diverse human populations. *Nature* 467(7311):52–58.
- Belsky J, Pluess M. 2009. Beyond diathesis stress: Differential susceptibility to environmental influences. *Psychol Bull* 135(6):885–908.
- Browning BL, Browning SR. 2009. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. *Am J Hum Genet* 84(2):210–223.
- Cross-Disorder Group of the Psychiatric Genomics Consortium. 2013. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nature Genetics* 45:984–994 doi: 10.1038/ng.2711.
- Hasin DS, Goodwin RD, Stinson FS, Grant BF. 2005. Epidemiology of major depressive disorder—Results from the National Epidemiologic Survey on Alcoholism and Related Conditions. *Arch Gen Psychiatry* 62(10):1097–1106.
- Howrigan DP, Simonson MA, Keller MC. 2011. Detecting autozygosity through runs of homozygosity: A comparison of three autozygosity detection algorithms. *BMC Genomics* 12:460.
- Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Muller-Myhsok B. 2009. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. *Arch Gen Psychiatry* 66(9):966–975.
- Keller MC, Simonson MA, Ripke S, Neale BM, Gejman PV, Howrigan DP, Lee SH, Lencz T, Levinson DF, Sullivan PF. 2012. Runs of homozygosity implicate autozygosity as a schizophrenia risk factor. *PLoS Genet* 8(4): e1002656.
- Keller MC, Visscher PM, Goddard ME. 2011. Quantification of inbreeding due to distant ancestors and its detection using dense single nucleotide polymorphism data. *Genetics* 189(1):237–249.
- Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS. 2003. The epidemiology of major depressive disorder—Results from the National Comorbidity Survey Replication (NCS-R). *JAMA* 289(23):3095–3105.
- Levinson DF. 2006. The genetics of depression: A review. *Biol Psychiatry* 60(2):84–92.
- Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K, Weale ME, Schosser A, Paredes UM, Rivera M, Craddock N, Owen MJ, Jones L, Jones I, Korszun A, Aitchison KJ, Shi JX, Quinn JP, MacKenzie A, Vollenweider P, Waeber G, Heath S, Lathrop M, Muglia P, Barnes MR, Whittaker JC, Tozzi F, Holsboer F, Preisig M, Farmer AE, Breen G, Craig IW, McGuffin P. 2010. Genome-wide association study of major recurrent depression in the UK population. *Am J Psychiatry* 167(8):949–957.
- McGuffin P, Katz R, Watkins S, Rutherford J. 1996. A hospital-based twin register of the heritability of DSM-IV unipolar depression. *Arch Gen Psychiatry* 53(2):129–136.
- McQuillan R, Eklund N, Pirastu N, Kuningas M, McEvoy BP, Esko T, Corre T, Davies G, Kaakinen M, Lyytikäinen LP, Kristiansson K, Havulinna AS, Gogele M, Vitart V, Tenesa A, Aulchenko Y, Hayward C, Johansson A, Boban M, Ulivi S, Robino A, Boraska V, Igl W, Wild SH, Zgaga L, Amin N, Theodoratou E, Polasek O, Grotto G, Lopez LM, Sala C, Lahti J, Laatikainen T, Prokopenko I, Kals M, Viikari J, Yang J, Pouta A, Estrada K, Hofman A, Freimer N, Martin NG, Kahonen M, Milani L, Heliövaara M, Vartiainen E, Raikonen K, Masciullo C, Starr JM, Hicks AA, Esposito L, Kolcic I, Farrington SM, Oostra B, Zemunik T, Campbell H, Kirin M, Pehlic M, Faletta F, Porteous D, Pistis G, Widen E, Salomaa V, Koskinen S, Fischer K, Lehtimäki T, Heath A, McCarthy MI, Rivadeneira F, Montgomery GW, Tiemeier H, Hartikainen AL, Madden PA, d'Adamo P, Hastie ND, Gyllenstein U, Wright AF, van Duijn CM, Dunlop M, Rudan I, Gasparini P, Pramstaller PP, Deary IJ, Toniolo D, Eriksson JG, Jula A, Raitakari OT, Metspalu A, Perola M, Jarvelin MR, Uitterlinden A, Visscher PM, Wilson JF. 2012. Evidence of inbreeding depression on human height. *PLoS Genet* 8(7): e1002655.
- Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ, Antoniadou A, Domenici E, Perry J, Rothen S, Vandeleur CL, Mooser V, Waeber G, Vollenweider P, Preisig M, Lucae S, Muller-Myhsok B, Holsboer F, Middleton LT, Roses AD. 2010. Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. *Mol Psychiatry* 15(6):589–601.
- Nesse RM. 1999. Proximate and evolutionary studies of anxiety, stress and depression: Synergy at the interface. *Neurosci Biobehav Rev* 23(7):895–903.
- Power RA, Kyaga S, Uher R, Maccabe JH, Langstrom N, Landen M, McGuffin P, Lewis CM, Lichtenstein P, Svensson AC. 2013. Fecundity of patients with schizophrenia, autism, bipolar disorder, depression, anorexia nervosa, or substance abuse vs their unaffected siblings. *Arch Gen Psychiatry* 70(1):22–30.

- Psychiatric Genomics Consortium MDD Working Group. 2012. A mega-analysis of genome-wide association studies for major depressive disorder. *Mol Psychiatry* 18(4):497–511.
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. 2007. PLINK: A tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81(3):559–575.
- Rietschel M, Mattheisen M, Frank J, Treutlein J, Degenhardt F, Breuer R, Steffens M, Mier D, Esslinger C, Walter H, Kirsch P, Erk S, Schnell K, Herms S, Wichmann HE, Schreiber S, Jockel KH, Strohmaier J, Roeske D, Haenisch B, Gross M, Hoefels S, Lucae S, Binder EB, Wienker TF, Schulze TG, Schmal C, Zimmer A, Juraeva D, Brors B, Bettecken T, Meyer-Lindenberg A, Muller-Myhsok B, Maier W, Nothen MM, Cichon S. 2010. Genome-wide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression. *Biol Psychiatry* 68(6):578–585.
- Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DH, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, De Hert M, Jonsson EG, Bitter I, Pietilainen OP, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Borglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, de Haan L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Gill M, Glenthøj B, Godard S, Hamshere M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jurgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang KY, Lichtenstein P, Lieberman JA, Linszen DH, Lonnqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nothen MM, O'Dushlaine CT, Olincy A, Olsen L, O'Neill FA, Orntoft TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quested D, Quinn EM, Rasmussen HB, Rethelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CC, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, van den Oord E, van Os J, van Winkel R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O'Donovan MC, Daly MJ, Gejman PV. 2011. Genome-wide association study identifies five new schizophrenia loci. *Nat Genet* 43(10):969–976.
- Rudan I, Rudan D, Campbell H, Carothers A, Wright A, Smolej-Narancic N, Janicijevic B, Jin L, Chakraborty R, Deka R, Rudan P. 2003. Inbreeding and risk of late onset complex disease. *J Med Genet* 40(12):925–932.
- Schulze TG, Akula N, Breuer R, Steele J, Nalls MA, Singleton AB, Degenhardt FA, Nothen MM, Cichon S, Rietschel M, McMahon FJ. 2012. Molecular genetic overlap in bipolar disorder, schizophrenia, and major depressive disorder. *World J Biol Psychiatry*. [epub ahead of print]
- Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA, Lawson WB, DePaulo JR, Gejman PV, Sanders AR, Johnson JK, Adams P, Chaudhury S, Jancic D, Evgrafov O, Zvinyatskovskiy A, Ertman N, Gladis M, Neimanas K, Goodell M, Hale N, Ney N, Verma R, Mirel D, Holmans P, Levinson DF. 2011. Genome-wide association study of recurrent early-onset major depressive disorder. *Mol Psychiatry* 16(2):193–201.
- Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM, Garriock HA, Yokoyama JS, McGrath PJ, Peters EJ, Scheftner WA, Coryell W, Lawson WB, Jancic D, Gejman PV, Sanders AR, Holmans P, Slager SL, Levinson DF, Hamilton SP. 2011. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. *Mol Psychiatry* 16(2):202–215.
- Sklar P, Ripke S, Scott LJ, Andreassen OA, Cichon S, Craddock N, Edenberg HJ, Nurnberger JI Jr, Rietschel M, Blackwood D, Corvin A, Flickinger M, Guan W, Mattingsdal M, McQuillin A, Kwan P, Wienker TF, Daly M, Dudbridge F, Holmans PA, Lin D, Burmeister M, Greenwood TA, Hamshere ML, Muglia P, Smith EN, Zandi PP, Nievergelt CM, McKinney R, Shilling PD, Schork NJ, Bloss CS, Foroud T, Koller DL, Gershon ES, Liu C, Badner JA, Scheftner WA, Lawson WB, Nwulia EA, Hipolito M, Coryell W, Rice J, Byerley W, McMahon FJ, Schulze TG, Berrettini V, Lohoff FW, Potash JB, Mahon PB, McInnis MG, Zollner S, Zhang P, Craig DW, Szelinger S, Barrett TB, Breuer R, Meier S, Strohmaier J, Witt SH, Tozzi F, Farmer A, McGuffin P, Strauss J, Xu W, Kennedy JL, Vincent JB, Matthews K, Day R, Ferreira MA, O'Dushlaine C, Perlis R, Raychaudhuri S, Ruderfer D, Hyoun PL, Smoller JW, Li J, Absher D, Thompson RC, Meng FG, Schatzberg AF, Bunney WE, Barchas JD, Jones EG, Watson SJ, Myers RM, Akil H, Boehnke M, Chambert K, Moran J, Scolnick E, Djurovic S, Melle I, Morken G, Gill M, Morris D, Quinn E, Muhleisen TW, Degenhardt FA, Mattheisen M, Schumacher J, Maier W, Steffens M, Propping P, Nothen MM, Anjorin A, Bass N, Gurling H, Kandaswamy R, Lawrence J, McGhee K, McIntosh A, McLean AW, Muir WJ, Pickard BS, Breen G, St Clair D, Caesar S, Gordon-Smith K, Jones L, Fraser C, Green EK, Grozeva D, Jones IR, Kirov G, Moskvina V, Nikolov I, O'Donovan MC, Owen MJ, Collier DA, Elkin A, Williamson R, Young AH, Ferrier IN, Stefansson K, Stefansson H, Thornorgeirsson T, Steinberg S, Gustafsson O, Bergen SE, Nimgaonkar V, Hultman C, Landen M, Lichtenstein P, Sullivan P, Schalling M, Osby U, Backlund L, Frisen L, Langstrom N, Jamain S, Leboyer M, Etain B, Bellivier F, Petursson H, Sigursson E, Muller-Mysok B, Lucae S, Schwarz M, Schofield PR, Martin N, Montgomery GW, Lathrop M, Oskarsson H, Bauer M, Wright A, Mitchell PB, Hautzinger M, Reif A, Kelsoe JR, Purcell SM. 2011. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nat Genet* 43(10):977–983.
- Skol AD, Scott LJ, Abecasis GR, Boehnke M. 2006. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. *Nat Genet* 38(2):209–213.
- StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP.
- Sullivan PF, de Geus EJC, Willemsen G, James MR, Smit JH, Zandbelt T, Arolt V, Baune BT, Blackwood D, Cichon S, Coventry WL, Domschke K, Farmer A, Fava M, Gordon SD, He Q, Heath AC, Heutink P, Holsboer F, Hoogendijk WJ, Hottenga JJ, Hu Y, Kohli M, Lin D, Lucae S, MacIntyre DJ, Maier W, McGhee KA, McGuffin P, Montgomery GW, Muir WJ, Nolen WA, Nothen MM, Perlis RH, Pirolo K, Posthuma D, Rietschel M, Rizzu P, Schosser A, Smit AB, Smoller JW, Tzeng JY, van Dyck R, Verhage M, Zitman FG, Martin NG, Wray NR, Boomsma DI, Penninx BWJH. 2009. Genome-wide association for major depressive disorder: A possible role for the presynaptic protein piccolo. *Mol Psychiatry* 14(4):359–375.
- Sullivan PF, Kendler KS, Neale MC. 2003. Schizophrenia as a complex trait—Evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry* 60(12):1187–1192.
- Sullivan PF, Neale MC, Kendler KS. 2000. Genetic epidemiology of major depression: Review and meta-analysis. *Am J Psychiatry* 157(10):1552–1562.

Watson PJ, Andrews PW. 2002. Toward a revised evolutionary adaptationist analysis of depression: The social navigation hypothesis. *J Affect Disord* 72(1):1–14.

Wray NR, Pergadia ML, Blackwood DHR, Penninx BWJH, Gordon SD, Nyholt DR, Ripke S, MacIntyre DJ, McGhee KA, Maclean AW, Smit JH, Hottenga JJ, Willemsen G, Middeldorp CM, de Geus EJC, Lewis CM, McGuffin P, Hickie IB, van den Oord EJCG, Liu JZ, Macgregor S, McEvoy BP, Byrne EM, Medland SE, Statham DJ, Henders AK, Heath AC, Montgomery GW, Martin NG, Boomsma DI, Madden PAF, Sullivan

PF. 2012. Genome-wide association study of major depressive disorder: New results, meta-analysis, and lessons learned. *Mol Psychiatry* 17(1):36–48.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher's web-site.